We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella

By LabMedica International staff writers
Posted on 22 Jun 2026

Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy. More...

Determining how this organism circulates outside hospitals has remained unclear, limiting targeted surveillance. Genomic analysis of large, representative isolate sets can clarify dissemination and resistance mechanisms. Researchers now report a nationwide assessment that identifies widespread, underrecognized community reservoirs across the United States.

At the Hackensack Meridian Center for Discovery and Innovation (CDI), in collaboration with Quest Diagnostics, investigators analyzed more than 2,000 Klebsiella pneumoniae isolates collected across 42 U.S. states. The study, published in Nature Communications as “Nationwide spread of multidrug resistant Klebsiella pneumoniae across U.S. communities,” leveraged a national diagnostic network to assemble a diverse sample set. Quest Diagnostics provided deidentified culture isolates classified as antibiotic resistant, which CDI then sequenced to characterize strain diversity and resistance determinants.

The analysis indicates that plasmid-borne drivers underpin the spread of resistance, with CTX-M-15 identified as a principal gene transferring between bacteria. According to the findings, this element has disseminated to hundreds of strains and is associated with both antimicrobial resistance traits and tolerance to stress and metal exposure, potentially enhancing survival outside human hosts. Geographic patterns showed regional, statewide, and multistate dissemination, consistent with underrecognized community reservoirs.

Across the more than 2,000 screened samples, 267 multidrug-resistant sequence types were identified. Two-thirds of specimens were from female patients and about three-quarters from individuals older than 60 years. All isolates examined were classified as multidrug resistant, and nearly 70% were resistant to three common oral agents—fluoroquinolones, Bactrim, and nitrofurantoin—indicating that, for some patients, injectable antibiotics may be the only viable option.

The work situates community transmission within a broader trend, building on prior observations of expanding extended-spectrum beta-lactamase (ESBL) reservoirs and a U.S. Centers for Disease Control and Prevention study that documented a 53.3% rise in ESBL-producing bacteria between 2012 and 2017. The authors describe the present dataset as a baseline for ongoing risk tracking. While strengths include national scope and a focus on community infections, a key limitation is the absence of detailed patient medical histories, which constrains inference about infection sources.

Related Links
Hackensack Meridian Center for Discovery and Innovation


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The automated multiplex PCR assay runs on the BioFire Spotfire Vaginitis System, bringing molecular vaginitis testing to the point of care (Photo courtesy of bioMérieux)

Molecular Vaginitis Panel Gains FDA Clearance and CLIA Waiver for Point-of-Care Use

Vaginitis affects most women at least once in their lifetime and can cause painful, disruptive symptoms. Common causes include bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis, reflecting... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: The CE-marked software IVD combines digital histopathology and clinicopathological data to generate a prognostic classification (Image Credit: Shutterstock)

Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer

In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. However, individual risks... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.